Sort by
Previous Page Page 1 of 34 Next Page
  1. Research

    Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia

    The CXCR4-CXCL12 axis plays an important role in the chronic lymphocytic leukemia (CLL)-microenvironment interaction. Overexpression of CXCR4 has been reported in different hematological malignancies including...

    Manoj K. Kashyap, Carlos I. Amaya-Chanaga, Deepak Kumar, Brett Simmons, Nanni Huser, Yin Gu, Max Hallin, Kevin Lindquist, Rolla Yafawi, Michael Y. Choi, Ale-Ali Amine, Laura Z. Rassenti, Cathy Zhang, Shu-Hui Liu, Tod Smeal, Valeria R. Fantin…

    Journal of Hematology & Oncology 2017 10:112

    Published on: 19 May 2017

  2. Research

    The chimeric monoclonal antibody MHCSZ-123 against human von Willebrand factor A3 domain inhibits high-shear arterial thrombosis in a Rhesus monkey model

    SZ-123, a murine monoclonal antibody that targets the human von Willebrand factor (VWF) A3 domain and blocks the binding of collagen, is a powerful antithrombotic. In a Rhesus monkey model of thrombosis, SZ-12...

    Shundong Ji, Miao Jiang, Bin Yan, Fei Shen, Yang He, Aini Wan, Lijun Xia, Changgeng Ruan and Yiming Zhao

    Journal of Hematology & Oncology 2017 10:111

    Published on: 19 May 2017

  3. Review

    Clinical applications of PD-L1 bioassays for cancer immunotherapy

    Programmed death ligand 1 (PD-L1) has emerged as a biomarker that can help to predict responses to immunotherapies targeted against PD-L1 and its receptor (PD-1). Companion tests for evaluating PD-L1 expressio...

    Delong Liu, Shuhang Wang and Wendy Bindeman

    Journal of Hematology & Oncology 2017 10:110

    Published on: 17 May 2017

  4. Research

    Intrathymic injection of hematopoietic progenitor cells establishes functional T cell development in a mouse model of severe combined immunodeficiency

    Even though hematopoietic stem cell transplantation can be curative in patients with severe combined immunodeficiency, there is a need for additional strategies boosting T cell immunity in individuals sufferin...

    Andrea Z. Tuckett, Raymond H. Thornton, Richard J. O’Reilly, Marcel R. M. van den Brink and Johannes L. Zakrzewski

    Journal of Hematology & Oncology 2017 10:109

    Published on: 16 May 2017

  5. Research

    Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study

    In our previous SMC NB-2004 study of patients with high-risk neuroblastomas, which incorporated total-body irradiation (TBI) with second high-dose chemotherapy and autologous stem cell transplantation (HDCT/au...

    Ji Won Lee, Sanghoon Lee, Hee Won Cho, Youngeun Ma, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Eun Joo Cho, Suk-Koo Lee and Do Hoon Lim

    Journal of Hematology & Oncology 2017 10:108

    Published on: 16 May 2017

  6. Research

    An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets

    A microRNA (miRNA) collection on the imprinted 14q32 MEG3 region has been associated with outcome in osteosarcoma. We assessed the clinical utility of this miRNA set and their association with methylation status.

    Katherine E. Hill, Andrew D. Kelly, Marieke L. Kuijjer, William Barry, Ahmed Rattani, Cassandra C. Garbutt, Haydn Kissick, Katherine Janeway, Antonio Perez-Atayde, Jeffrey Goldsmith, Mark C. Gebhardt, Mohamed S. Arredouani, Greg Cote, Francis Hornicek, Edwin Choy, Zhenfeng Duan…

    Journal of Hematology & Oncology 2017 10:107

    Published on: 15 May 2017

  7. Research

    Platelet desialylation is a novel mechanism and a therapeutic target in thrombocytopenia during sepsis: an open-label, multicenter, randomized controlled trial

    Studies in murine models suggested that platelet desialylation was an important mechanism of thrombocytopenia during sepsis.

    Mei-feng Li, Xiao-li Li, Kai-liang Fan, Ying-yi Yu, Jing Gong, Shu-ying Geng, Ya-feng Liang, Ling Huang, Ji-hua Qiu, Xing-han Tian, Wen-ting Wang, Xiao-lu Zhang, Qing-xia Yu, Yuan-feng Zhang, Peng Lin, Li-na Wang…

    Journal of Hematology & Oncology 2017 10:104

    Published on: 11 May 2017

  8. Research

    Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial

    Allogeneic hematopoietic stem cell transplantation (HSCT), the most widely used potentially curable cellular immunotherapeutic approach in the treatment of hematological malignancies, is limited by life-threat...

    Chongsheng Qian, Arnaud Campidelli, Yingying Wang, Huili Cai, Véronique Venard, Hélène Jeulin, Jean Hugues Dalle, Cécile Pochon, Maud D’aveni, Benedicte Bruno, Catherine Paillard, Stéphane Vigouroux, Charlotte Jubert, Patrice Ceballos, Aude Marie-Cardine, Claire Galambrun…

    Journal of Hematology & Oncology 2017 10:102

    Published on: 8 May 2017

  9. Review

    Checkpoint inhibitors in hematological malignancies

    Inhibitory molecules such as PD-1, CTLA-4, LAG-3, or TIM-3 play a role to keep a balance in immune function. However, many cancers exploit such molecules to escape immune surveillance. Accumulating data suppor...

    Chi Young Ok and Ken H. Young

    Journal of Hematology & Oncology 2017 10:103

    Published on: 8 May 2017

  10. Review

    Wnt/beta-catenin pathway: modulating anticancer immune response

    Wnt/β-catenin signaling, a highly conserved pathway through evolution, regulates key cellular functions including proliferation, differentiation, migration, genetic stability, apoptosis, and stem cell renewal....

    Sachin Gopalkrishna Pai, Benedito A. Carneiro, Jose Mauricio Mota, Ricardo Costa, Caio Abner Leite, Romualdo Barroso-Sousa, Jason Benjamin Kaplan, Young Kwang Chae and Francis Joseph Giles

    Journal of Hematology & Oncology 2017 10:101

    Published on: 5 May 2017

  11. Research

    Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages

    Solid tumors residing in tissues and organs leave footprints in circulation through circulating tumor cells (CTCs) and circulating tumor DNAs (ctDNA). Characterization of the ctDNA portraits and comparison wit...

    Meng Yang, Umit Topaloglu, W. Jeffrey Petty, Matthew Pagni, Kristie L. Foley, Stefan C. Grant, Mac Robinson, Rhonda L. Bitting, Alexandra Thomas, Angela T. Alistar, Rodwige J. Desnoyers, Michael Goodman, Carol Albright, Mercedes Porosnicu, Mihaela Vatca, Shadi A. Qasem…

    Journal of Hematology & Oncology 2017 10:100

    Published on: 4 May 2017

  12. Letter to the Editor

    Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis

    We studied non-driver mutations in 62 subjects with myeloproliferative neoplasm (MPN)-associated myelofibrosis upon diagnosis, including 45 subjects with primary myelofibrosis (PMF) and 17 with post-polycythemia

    Bing Li, Robert Peter Gale, Zefeng Xu, Tiejun Qin, Zhen Song, Peihong Zhang, Jie Bai, Lei Zhang, Yue Zhang, Jinqin Liu, Gang Huang and Zhijian Xiao

    Journal of Hematology & Oncology 2017 10:99

    Published on: 2 May 2017

  13. Review

    Emerging therapies for breast cancer

    HER2 and CDK4/6 are undoubted two most important biological targets for breast cancer. Anti-HER2 treatments enhance objective response and progression-free survival/disease-free survival as well as overall sur...

    Xichun Hu, Wei Huang and Minhao Fan

    Journal of Hematology & Oncology 2017 10:98

    Published on: 28 April 2017

  14. Review

    Immunotherapy in genitourinary malignancies

    Treatment of cancer patients involves a multidisciplinary approach including surgery, radiotherapy, and chemotherapy. Traditionally, patients with metastatic disease are treated with combination chemotherapies...

    Kathan Mehta, Keyur Patel and Rahul A. Parikh

    Journal of Hematology & Oncology 2017 10:95

    Published on: 24 April 2017

  15. Review

    Recent advances of highly selective CDK4/6 inhibitors in breast cancer

    Uncontrolled cell division is the hallmark of cancers. Full understanding of cell cycle regulation would contribute to promising cancer therapies. In particular, cyclin-dependent kinases 4/6 (CDK4/6), which ar...

    Hanxiao Xu, Shengnan Yu, Qian Liu, Xun Yuan, Sridhar Mani, Richard G. Pestell and Kongming Wu

    Journal of Hematology & Oncology 2017 10:97

    Published on: 24 April 2017

  16. Review

    The use of immunotherapy in the treatment of melanoma

    Patients with advanced melanoma have a compromised anti-tumor immune response leading to tumor immune tolerance and a tumor microenvironment conducive to disease progression. Immunotherapy that successfully ov...

    Tala Achkar and Ahmad A. Tarhini

    Journal of Hematology & Oncology 2017 10:88

    Published on: 24 April 2017

  17. Review

    Immunotherapy in hematologic malignancies: past, present, and future

    The field of immunotherapy in cancer treatments has been accelerating over recent years and has entered the forefront as a leading area of ongoing research and promising therapies that have changed the treatme...

    Annie Im and Steven Z. Pavletic

    Journal of Hematology & Oncology 2017 10:94

    Published on: 24 April 2017

  18. Review

    The next generation of immunotherapy: keeping lung cancer in check

    Lung cancer is the deadliest malignancy with more cancer deaths per year than the next three cancers combined. Despite remarkable advances in targeted therapy, advanced lung cancer patients have not experience...

    Ashwin Somasundaram and Timothy F. Burns

    Journal of Hematology & Oncology 2017 10:87

    Published on: 24 April 2017

  19. Research

    A novel lncRNA uc.134 represses hepatocellular carcinoma progression by inhibiting CUL4A-mediated ubiquitination of LATS1

    Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, and tumor recurrence and metastasis are major factors that contribute to the poor outcome of patients with HCC. Long noncoding R...

    Wen Ni, Yuqin Zhang, Zetao Zhan, Feng Ye, Yonghao Liang, Jing Huang, Keli Chen, Longhua Chen and Yi Ding

    Journal of Hematology & Oncology 2017 10:91

    Published on: 19 April 2017

  20. Research

    DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma

    The B cell maturation process involves multiple steps, which are controlled by relevant pathways and transcription factors. The understanding of the final stages of plasma cell (PC) differentiation could provi...

    Dalia Quwaider, Luis A. Corchete, Irena Misiewicz-Krzeminska, María E. Sarasquete, José J. Pérez, Patryk Krzeminski, Noemí Puig, María Victoria Mateos, Ramón García-Sanz, Ana B. Herrero and Norma C. Gutiérrez

    Journal of Hematology & Oncology 2017 10:92

    Published on: 18 April 2017

  21. Review

    Emerging therapies for acute myeloid leukemia

    Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity. Despite the advances in our understanding of its pathobiology, the chemotherapy-directed management has remained largely ...

    Caner Saygin and Hetty E. Carraway

    Journal of Hematology & Oncology 2017 10:93

    Published on: 18 April 2017

Previous Page Page 1 of 34 Next Page
JHO logo